In the present study, the role of decreased renal function on resistin was explored. 
INTRODUCTION
The recent discovery of resistin, a 12.5-kDa cysteine-rich protein secreted mainly by adipocytes and apparently inhibiting insulin action in vitro,
(1-3) has generated much interest. Resistin, like adiponectin, circulates in serum in at least two distinct dimeric assembly forms that appear to have different levels of bioactivity.
(4)
Administration of recombinant resistin to mice impairs glucose tolerance and decreases the action of insulin, whereas an increase in insulin sensitivity is noted when the animals are treated with resistin-neutralizing antibodies.
(1)
Although several studies
(1,5)
implicate resistin as an important regulator of glucose levels in mice, the role of resistin in human syndromes of insulin resistance, such as uremia, is far from clear.
(1,6-8)
Indeed, the few studies (9-11) that have so far been performed in non-renal patients have been unable to find a significant relationship between serum glucose levels or markers of insulin resistance and circulating resistin or resistin expression by subcutaneous adipocytes. Similar results were observed in a small study of 30 CKD patients by Kielstein et al.
(6)
Insulin resistance is the central pathophysiological process of the metabolic syndrome,
(1) a wellestablished and major risk factor for the development of cardiovascular disease.
(12,13) Chronic kidney disease (CKD) of any etiology is associated with insulin resistance of primarily peripheral tissues resulting in varying degrees of hyperinsulinemia and glucose intolerance.
(14,15) Decreased response to insulin is manifest already in mild renal dysfunction (16) and progresses with declining glomerular filtration rate (GFR), (17) only to improve slightly at the initiation of renal replacement therapy.
(17)
The proposed link(s) between declining renal function and insulin resistance appear to act mainly in peripheral tissues, 
SUBJECTS & METHODS

Subjects:
Subjects enrolled in the present study were classified into 4 groups (total 83 subjects). (a,b,c,d) under each group indicate a non-significant difference among groups. Different letters (a,b,c,d) under each group indicate significant difference among groups. Table 1 shows demographic data, serum creatinine, eGFR, fasting plasma glucose (FPG), fasting plasma insulin (FPI), insulin resistance (HOMA-IR) and HbA1c% in the studied groups. All groups were matched regarding age, sex and BMI. Creatinine was significantly higher in dialysis group than other groups (P<0.001). eGFR was significantly higher in pos-transplantation group than conservative group (P<0.001).However, it was still significantly lower than control group (P<0.001) . As dialysis patients were anuric, no GFR was estimated in that group. As regards markers of glucose metabolism, FPI and HOMA-IR were significantly higher in dialysis group and conservative group than other groups (P<0.001). There was no statistically significant difference in FPG and HbA1c among groups. Total cholesterol was significantly higher in dialysis group and conservative group than control and post-transplantation groups (P<0.01).There was no statistically significant difference in TAG among groups. (a,b,c,d) under each group indicate significant difference among groups. Table ( 2) shows the levels of resistin, IL6 and hs CRP in the studied groups. All were significantly higher in dialysis group than other groups (P<0.001). Resistin and hs CRP decreased significantly after transplantation but still were significantly higher than control group (P<0.001). However, there was no significant difference in IL6 between post-transplantation and control groups. 
RESULTS
DISCUSSION
The present study demonstrated that circulating serum resistin levels, like other adipokines such as leptin and adiponectin (34,35) were markedly elevated in patients with renal function impairment. Several factors might contribute to elevated circulating resistin levels in CKD. First, a strong impact of GFR on circulating fasting serum levels of resistin was demonstrated .Thus, the current data confirm the association previously reported by Kielstein et al.
(6) in a cohort of CKD patients. As resistin is a 12.5 kDa protein, it could be hypothesized that this small protein will have similar renal clearance characteristics as β 2 -microglobulin (13.7 kDa), which has been extensively studied.
(36) If this is true, it might be expected that resistin secretion through the kidneys is the major pathway of elimination, and current dialysis techniques will only partially be able to remove excess resistin from the circulation. Clearly, in future clinical studies evaluating circulating resistin levels, renal function must be taken into account.
Another major finding of the present study is the association between serum levels of resistin and various biomarkers of inflammation, confirming studies in patients without renal function impairment.
(37-40)
Recently, it has become apparent that CKD is a state of chronic inflammation that is associated with significant increases in serum proinflammatory cytokine levels already at moderate levels of renal function impairment. Although fat mass is likely an important source of both resistin and several proinflammatory cytokines, (45) suggested that this effect was mainly due to modulation of hepatic insulin resistance.
Although resistin seems to be strongly associated with insulin resistance in mice models, several recent studies have questioned the hypothesis that resistin is a significant determinant of insulin resistance in humans. First, Janke et al.
(9) found low levels of resistin expression in subcutaneous adipocytes and no correlation with insulin resistance. Similarly, Heilbronn et al.
(10) found that serum resistin concentrations did not differ among non-obese, obese and obese diabetic subjects, nor were they significantly correlated with glucose metabolism during a hyperinsulinemic glucose clamp across the groups. Finally, when comparing three different immunoassays for resistin, Pfützner et al.
(11) found no correlation between fasting serum levels of resistin and any of the measured parameters of insulin resistance or with blood lipids in patients with type II diabetes mellitus. In the present study no significant correlation between fasting serum resistin levels and marker of insulin resistance (HOMA-IR) was found.
The present results agree with those of Kielstein et al. 
Another point of criticism might be that we do not know if resistin levels in the present study represent active resistin or if an accumulation of inactive resistin metabolites accounts for the major part of the increased plasma resistin concentration observed in CKD. Also, circulating resistin levels may not accurately reflect local resistin action at the tissue level.
Finally, the use of antihypertensive medications has been reported to influence insulin sensitivity. Thus, while β-blockers appear to decrease insulin sensitivity, most (but not all) ACE inhibitors (ACEI) and calcium blockers appear to improve it.
(51) As the majority of these patients were taking more than one class of drugs, it might be thought that this confounder is of minor importance and will not unduly affect the reported results. Indeed, no significant differences were found in HOMA-IR between patients taking ACEI and those not taking ACEI (not presented data).
In summary, the present data support the hypothesis that inflammation is associated with hyper-resistinemia. As no significant relationship was found between serum resistin levels and insulin resistance, resistin is not a likely mediator of insulin resistance in patients with renal disease. Renal function is an important factor to take into account in clinical studies relating insulin sensitivity to inflammatory biomarkers in CKD. 
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